Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01116648
Title Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

peritoneum cancer

Her2-receptor negative breast cancer

fallopian tube cancer

triple-receptor negative breast cancer

ovary epithelial cancer



Cediranib + Olaparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.